Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea
- Author:
Kyuho KIM
1
;
Sung Hee CHOI
Author Information
- Publication Type:Editorial
- From:Diabetes & Metabolism Journal 2021;45(4):502-504
- CountryRepublic of Korea
- Language:English
